Skip to content

Repetitive transcranial magnetic stimulation and intermittent theta burst stimulation in schizophrenia

The Comparison of effectiveness of repetitive TMS and iTBS on negative Symptoms and Cognition in Patients with Schizophrenia:a study randomized and double blind

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT138903254191N1
Enrollment
30
Registered
2011-01-09
Start date
2011-01-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: 15 Hz rTMS are applied during 20 to 30 minutes in 20 sessions. Intervention 2: 50Hz theta burst ia applied during 5 to 10 minutes in 20 sessions. Intervention 3: Sham coil in 20 sessio
Treatment - Devices
Placebo
15 Hz rTMS are applied during 20 to 30 minutes in 20 sessions
50Hz theta burst ia applied during 5 to 10 minutes in 20 sessions
Sham coil in 20 sessions

Sponsors

Atieh comprehensive psyche and nerve center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: outpatients male and female with the range of 18-50 years of age, The diagnosis of Schizophrenia according to DSM-IV-TR, Completion of Consent Form, Being Under Supervision of a psychiatrist, being able to adhere to treatment Schedule, having stable symptoms as defined by not requiring a change in Antipsychotic medication for at least 4 weeks or at least 2 weeks for psychotropic agents prior to entering the Study Exclusion Criteria: The history of rTMS treatment for any reason, Intracranial Implant and other ferromagnetic materials close to the head, Cardiac Pacemaker, drug Pumps, acute heart attack, the risk of Seizure with any reasons, high Intracranial pressure, The history of epilepsy or Seizure in the first relatives, any metal in Head, brain trauma, history of loss of consciousness for more than 5 minutes, pregnancy, breastfeeding, drug dependency, high risk of Suicide, significant positive symptoms

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Negative symptoms. Timepoint: Session One,Session ten, Session twenty. Method of measurement: Positive and negative symptom scale.;Cognitive functioning. Timepoint: Sessions One, ten, and twenty. Method of measurement: Neuropsychology Battery Tests.

Secondary

MeasureTime frame
Depression. Timepoint: Session One,Session ten, Session twenty. Method of measurement: Calgary depression for schizophrenia scale (CDSS).;Quality of life. Timepoint: Session One,Session ten, Session twenty. Method of measurement: Schizophrenia quality of life scale (SQLS).;Social Functioning. Timepoint: Sessions One, ten, and twenty. Method of measurement: Social and occupational functioning Assessment scale (SOFAS).

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026